Dr.Reddy’s Laboratories Ltd (NYSE:RDY) – Jefferies Financial Group issued their FY2022 earnings estimates for Dr.Reddy’s Laboratories in a research note issued on Sunday, May 19th. Jefferies Financial Group analyst P. Nahar anticipates that the company will post earnings per share of $2.22 for the year.

Several other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Dr.Reddy’s Laboratories from a “hold” rating to a “strong sell” rating in a research note on Wednesday. TheStreet downgraded Dr.Reddy’s Laboratories from a “b” rating to a “c” rating in a research note on Monday. Morgan Stanley downgraded Dr.Reddy’s Laboratories from an “overweight” rating to an “equal weight” rating in a research note on Monday. Finally, CL King upgraded Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research note on Monday, February 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $44.00.

Shares of RDY stock opened at $37.84 on Tuesday. Dr.Reddy’s Laboratories has a 1-year low of $28.49 and a 1-year high of $42.82. The company has a current ratio of 1.81, a quick ratio of 1.26 and a debt-to-equity ratio of 0.18. The firm has a market cap of $6.54 billion, a P/E ratio of 23.07 and a beta of 0.13.

A number of hedge funds have recently made changes to their positions in RDY. Nordea Investment Management AB purchased a new position in Dr.Reddy’s Laboratories during the 3rd quarter worth $1,320,000. Eqis Capital Management Inc. grew its stake in Dr.Reddy’s Laboratories by 8.0% during the 4th quarter. Eqis Capital Management Inc. now owns 12,027 shares of the company’s stock worth $453,000 after buying an additional 892 shares during the last quarter. Boston Common Asset Management LLC grew its stake in Dr.Reddy’s Laboratories by 17.8% during the 4th quarter. Boston Common Asset Management LLC now owns 14,390 shares of the company’s stock worth $543,000 after buying an additional 2,170 shares during the last quarter. Private Capital Group LLC grew its stake in Dr.Reddy’s Laboratories by 209.2% during the 4th quarter. Private Capital Group LLC now owns 739 shares of the company’s stock worth $28,000 after buying an additional 500 shares during the last quarter. Finally, Wetherby Asset Management Inc. grew its stake in Dr.Reddy’s Laboratories by 14.6% during the 4th quarter. Wetherby Asset Management Inc. now owns 13,219 shares of the company’s stock worth $499,000 after buying an additional 1,681 shares during the last quarter. Hedge funds and other institutional investors own 12.26% of the company’s stock.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Recommended Story: How Does the Quiet Period Work?

Earnings History and Estimates for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.